Shilpa Medicare Limited · NSE:SHILPAMED
Shilpa Medicare — Q3 FY2020 Earnings Presentation
23 slides from Shilpa Medicare's earnings presentation, Feb 11, 2020
Slide 1: Shilpa Medicare Limited – Exchange Filing Cover Letter
? Shilpa Medicare Limited .... Iaffordable Innovatingfor healthcare Manufacturers and Exporters 12-6-214/A1,Hyderabad Road, # of Bulk Drugs 584 135. Karnataka,lndia. RAICHUR - Phone: +91-8532 238704, Fax: +91-8532-238876 - CIN No. L8511 OKA 1987PLC008739 E-mail: info@vbshilpa.com Website: www.vbshil
Slide 2: Q3 & 9M FY20 Results Presentation
Q3 & 9M FY20 JADCHERLA PLANT Results Presentation Shilpa Medicare Limited (SML)
Slide 3: Disclaimer
Certain statements in this document may be forward-looking statements. Such forward looking Disclaimer statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ mat
Slide 4: Table of Contents
Table of Contents Inj. Packing Line: Jadcherla Plant Company Overview 4 Financial Performance 14 Way Forward 19 3
Slide 5: Company Overview
Company Overview Established presence in Active Specialized in Pharmaceutical oncology and non- oncology Ingredients (APIs) therapeutic areas, and Formulations for domestic & supported by strong R&D Robust research Affordable & international capability orientation resulting in Effective markets inno
Slide 6: Established Business Segments
Established Business Segments Description Capacities Manufacturing API products with highly API précised Isolator Technology. 9 dedicated Blocks for Oncology & 4 Blocks The facility is approved by USFDA, WHO-GMP, for Non Oncology EUGMP, TGA, PMDA, KFDA, TPD Multi-product capability for Oncol
Slide 7: Growth Business Segments
Growth Business Segments Description Capacities Company will pursue an aggressive IP strategy 2 Lines independent single use lines (1000L Biologicals to ring fence its bio similar and NBE assets bioreactor each) for production of MAbs from mammalian cells 3 of the top 15 biologic products in i
Slide 8: Strengths
R&D Competence Technology Edge SML’s Key Strengths Rich Scientific Talent Manufacturing Excellence 7
Slide 9: Research & Development Competence
Research & Development Competence API R&D centre aids development of Generics which meet international development standards R&D Formulation R&D centre develops Generic equivalents and super generics for global markets capabilities, a of Injectable and Oral Formulations primarily used vital componen
Slide 10: Technology Edge
Technology Edge Bilayer Compression inside Oncology isolator- Oral -Jadcherla Plant The Company has advanced in the field of ‘Targeted Therapy’ which has enabled the identification of neoplastic cells and development of novel targeted therapies The Company constantly works on reducing the prices
Slide 11: Rich Scientific Talent
Rich Scientific The Intellectual Property Management (IPM) team is Talent responsible for building a global generic product pipeline 300+ Provides stage wise IP-clearances during product/process development activities Scientists 300+ Provides frequent updates and alerts on relevant IP to R&D scienti
Slide 12: Patents Status as on Dec 31, 2019
Patents Status as on Dec 31, 2019 Patents Filings Granted Pending - API 199 31 168 - Formulation 52 5 47 - Films Topical & 44 2 42 Transdermal - Biologicals 6 2 4 - Others 18 1 17 TOTAL 319 41 278 11
Slide 13: Product Pipeline as on Dec 31, 2019
Product Pipeline as on Dec 31, 2019 Approved Particular Filings Pending (Including Tentative) US ANDA 22 13 9 - On SML’s Name - On Customer’s Name 19 12 7 TOTAL in US 41 25 16 - EU Filing 17 11 6 TOTAL ( in US & EU) 58 36 22 12
Slide 14: Manufacturing Excellence
Manufacturing Excellence Facility Location Facility Type Dharwad, Karnataka R & D Biologicals Facility Bangalore, Karnataka R & D (All segments except Biologics) Raichur Unit I API (Onco – Non Onco) Raichur Unit II API (Onco – Non Onco)& R&D API India Formulations (Onco & Adjuvant Therapy Jadcherla
Slide 15: Financial Performance
Oral Granulation Line - Jadcherla Plant Financial Performance 14
Slide 16: Abridged P&L Statement – Standalone
Abridged P&L Statement – Standalone (Rs. In Lakhs) Q3 Q3 Y-o-Y 9M 9M Y-o-Y Particulars FY20 FY19 Change (%) FY20 FY19 Change (%) Total Income (A+B+C+D) 21,939.6 16,149.9 36 61,641.5 50,509.0 22 Total Revenue from Operations (A+B+C) 21,692.9 15,717.1 38 60,803.8 49,286.1 23 • API (A) 11,707.7 11,230.
Slide 17: Abridged P&L Statement – Consolidated
Abridged P&L Statement - Consolidated (Rs. In Lakhs) Q3 Q3 Y-o-Y 9M 9M Y-o-Y Particulars FY20 FY19 Change (%) FY20 FY19 Change (%) Total Income (A+B) 24,010.8 17,655.5 36 69,881.9 54,451.0 28 Revenue from operations (A) 23,685.4 17,342.5 37 68,776.2 53,387.0 29 Other Income (B) 325.4 313.0 4 1,105.7
Slide 18: Results Snapshot (Standalone)
Results Snapshot (Standalone) Q3 FY20 vs. Q3 FY19 Division wise Revenue from Operations • Formulations revenues was higher on account of ( Rs. In Lakhs) launch of a new product in the US 11,708 11,231 • API revenues grew on the back of growth in oncology API business 9,549 • CRAMS revenue on downwar
Slide 19: Managing Director's Message
Managing Director’s Message Commenting on Q3 & 9M FY’20 performance, the Managing Director of Shilpa Medicare Limited said “We are glad to share our encouraging performance during the quarter. Revenues grew due to higher formulations sales. Even though our CRAMS revenue has been sluggish as we are e
Slide 20: Way Forward
Vial Washing Machine Inj. 2 - Jadcherla Plant Way Forward 19
Slide 21: Way Forward
Way Forward API Formulations Future Growth Businesses • Plan to commercialize • To attain economies of • Diversification into other therapeutic areas like biologics, 3-4 new molecules scale by increasing batch portfolio expansion to transdermal dosage forms and oral each year sizes thin films formul
Slide 22: About Shilpa Medicare Ltd.
About Shilpa Medicare Ltd. Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1989 at Raichur, Karnataka- India. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.
Slide 23: Thank You
Temple - Jadcherla Plant Thank You 22